Status:
COMPLETED
Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases
Lead Sponsor:
South Valley University
Conditions:
Bronchial Neoplasm Benign
Eligibility:
All Genders
35-70 years
Brief Summary
Purpose: Survivin is a common member of the inhibitors of the apoptosis protein (IAP) family with a dual role in promoting cell proliferation and preventing apoptosis. Fibulin-3, a matrix glycoprotein...
Detailed Description
Study design and participants The current prospective cohort study has been conducted with 73 patients of both sexes, with recently diagnosed benign and malignant respiratory diseases recruited from C...
Eligibility Criteria
Inclusion
- any patients with Benign or Malignant Respiratory Diseases and agree to included in the study
Exclusion
- Patients with renal failure, hepatic failure, severe cardiopulmonary compromise, coagulopathy or hemodynamically unstable were excluded
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT04413292
Start Date
January 1 2017
End Date
April 1 2020
Last Update
June 4 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.